Trial · NCT06536010
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
NCT06536010, Not applicable, Recruiting, Yang Xiaotian
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML. Trials, record NCT06536010. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06536010
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
- NCT number
- NCT06536010
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Yang Xiaotian
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
- First posted
- 2024-08-02
- Last updated
- 2024-08-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Remission (CR) | The period of 2 months from the start of treatment. | A. No symptoms or signs of leukemia cell infiltration, normal or near-normal life; B. Blood counts: Hb ≥ 100g/L (males) or ≥ 90g/L (females and children), absolute neutrophil count ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L. No leukemia cells in peripheral blood leukocyte classification; C. Bone marrow morphology: Less than or equal to 5% of myeloblasts (type I + type II) (primitive monocytes + immature monocytes or primitive lymphocytes + immature lymphocytes), normal red blood cells and megakaryocytes; D. No extramedullary leukemia (no lymphadenopathy, splenomegaly, skin/gum infiltration, testicular masses, central nervous system involvement). |
| Secondary | Partial Remission (PR) | The period of 1 month from the start of treatment. | Myeloblasts (type I + type II) (primitive monocytes + immature monocytes or primitive lymphocytes + immature lymphocytes) \> 5% but ≤ 20%; or one of the following criteria is met in clinical, blood counts, and bone marrow morphology for complete remission. |
| Secondary | Complete Remission with incomplete blood count recovery (CRi) | The period of 1 month from the start of treatment. | PLT \< 100 × 109/L or NE \< 1.5 × 109/L. Other criteria for CR should be met. |
| Secondary | Overall Response Rate (ORR) | The period of 4 months from the start of treatment. | CR+CRi+MLFS+PR |
| Secondary | Morphologic leukemia-free state (MLFS) | The period of 1 month from the start of treatment. | \< 5% of primitive cells in bone marrow; no immature cells with Auer rods; no persistent extramedullary leukemia; no requirement for normal blood cell recovery. |
| Secondary | Overall survival, OS | The period of 2 years from the start of treatment. | The time from the start of treatment to death or the end of follow-up, evaluated at 2 years after treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06536010
GET https://conductscience.org/api/trials/v1/NCT06536010/registered